Pietrantonio, Filomena
 Distribuzione geografica
Continente #
EU - Europa 57
AS - Asia 53
SA - Sud America 13
NA - Nord America 11
AF - Africa 1
Totale 135
Nazione #
IT - Italia 22
SG - Singapore 16
IN - India 15
BR - Brasile 13
CN - Cina 13
DE - Germania 13
US - Stati Uniti d'America 11
FR - Francia 8
GB - Regno Unito 6
KR - Corea 4
FI - Finlandia 2
ID - Indonesia 2
IE - Irlanda 2
SA - Arabia Saudita 2
CZ - Repubblica Ceca 1
DZ - Algeria 1
HK - Hong Kong 1
NL - Olanda 1
PL - Polonia 1
SE - Svezia 1
Totale 135
Città #
Hyderabad 10
Singapore 9
Stuttgart 7
Hefei 4
Seoul 4
Düsseldorf 3
Frankfurt am Main 3
Rome 3
Chandigarh 2
Dublin 2
Lusciano 2
Milan 2
Portsmouth 2
Recife 2
Turku 2
Ashburn 1
Bexley 1
Bom Princípio 1
Bragança Paulista 1
Bristol 1
Cajamar 1
Coon Rapids 1
Hong Kong 1
Ipatinga 1
Itajaí 1
Jakarta 1
Jeddah 1
Kalyān 1
London 1
Los Angeles 1
Malang 1
Manchester 1
Medina 1
Newark 1
Panchkula 1
Pimenta Bueno 1
Porto Alegre 1
Prague 1
Santos 1
Sorocaba 1
São Paulo 1
Uberaba 1
Warsaw 1
Waterford 1
Totale 86
Nome #
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 46
Cow’s Milk Consumption and Health: A Health Professional’s Guide 39
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 23
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 22
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: Lessons from the AtezoT RIBE study 10
Totale 140
Categoria #
all - tutte 586
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 586


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20231 0 0 0 0 0 0 0 0 0 1 0 0
2023/202418 0 9 2 2 2 1 0 0 0 0 2 0
2024/2025121 0 0 1 1 0 1 36 3 10 21 23 25
Totale 140